期刊文献+

miR-155在肝细胞癌中的表达及对肝癌细胞增殖的影响 被引量:2

Expression of miR-155 in primary hepatocellular carcinoma and its effect on tumor cell proliferation
在线阅读 下载PDF
导出
摘要 目的:检测微小RNA-155(miR-155)在肝癌组织中的表达并分析其对肝癌细胞增殖和细胞凋亡的影响.方法:采用TagMan MGB探针法荧光定量P C R分析42例原发性肝癌及对应的癌旁组织miR-155的表达;利用miR-155反义寡核苷酸(ASO-miR-155)降低肝癌细胞HepG2和SMMC7721中miR-155的表达;利用MTT比色法检测肝癌细胞增殖的变化,并通过流式细胞技术检测肝癌细胞早期凋亡情况.结果:42例肝癌及癌旁组织标本中,miR-155在52%(22/42)肝癌组织中的表达明显高于癌旁组织(P<0.05);利用脂质体将ASO-miR-155转染肝癌细胞HepG2和SMMC7721后,miR-155的表达明显降低,肝癌细胞HepG2和SMMC7721生长受到明显抑制;并且细胞的早期凋亡明显增加.结论:miR-155在肝癌组织中过表达,降低其表达能明显抑制肝癌细胞的生长并诱导细胞早期凋亡,miR-155有可能成为肝癌治疗的新靶点. AIM: To detect the expression of microRNA 155 (miR-155) in hepatocellular carcinoma and to analyze its influence on tumor cell proliferation and apoptosis. METHODS: The expression of miR-155 in 42 cases of primary liver cancer and matched tumor-adjacent normal tissue was detected by quantitative PCR. The expression of miR-155 in hepatoceUular carcinoma cell lines HepG2 and SMMC7721 was inhibited using a miR-155-spe- cific antisense oligonucleotide (ASO-miR-155), and cell proliferation and early apoptosis were then determined by MTT assay and flow cytom- etry, respectively. RESULTS: The positive rate of miR-155 expres- sion was significantly higher in hepatocellular carcinoma (52%) than in tumor-adjacent tissue (P 〈 0.05). After ASO-miR-155 was transfected into HepG2 and SMMC7721 cells using Lipo- fectamine, the expression of miR-155 was signifi- cantly reduced. MiR155 knockdown significantly inhibited growth and promoted early apoptosis of HepG2 and SMMC7721 cells. CONCLUSION: MiR-155 is overexpressed in hepatocellular carcinoma. Inhibition of miR-155 expression could inhibit growth and induce ear- ly apoptosis of hepatocellular carcinoma cells. MiR-155 may become a new target for the treat- ment of liver cancer.
出处 《世界华人消化杂志》 CAS 北大核心 2012年第19期1737-1741,共5页 World Chinese Journal of Digestology
关键词 原发性肝细胞癌 MIR-155 增殖 凋亡 Primary hepatocellular carcinoma MiR-155 Proliferation Apoptosis
  • 相关文献

参考文献30

  • 1Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
  • 2Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepato12008; 48 Suppl 1:S20-S37.
  • 3Jemal A, Bray F, Center MM, Ferlay J, Ward E, For- man D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
  • 4常宗宏,汪泳,吴汉平.肝癌的综合治疗及肿瘤抗血管联合疗法[J].世界华人消化杂志,2012,20(5):385-388. 被引量:6
  • 5Zeng Y. Principles of micro-RNA production and maturation. Oncogene 2006; 25:6156-6162.
  • 6Kloosterman WP, Plasterk RH. The diverse func- tions of microRNAs in animal development and disease. Dev Cell 2006; 11:441-450.
  • 7Sayed D, Abdellatif M. MicroRNAs in development and disease. Physiol Rev 2011; 91:827-887.
  • 8Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704-714.
  • 9Munker R, Calin GA. MicroRNA profiling in can- cer. Clin Sci (Lond) 2011; 121:141-158.
  • 10Szafranska AE, Davison TS, John J, Cannon T, SiposB, Maghnouj A, Labourier E, Hahn SA. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007; 26:4442-4452.

二级参考文献87

共引文献14

同被引文献23

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部